Moderna IncChange company Symbol lookupSelect an option...MRNA Moderna IncHYHG.EU ProShares High Yield-Interest Rate HedgedDIDIY DiDi Global IncAWK American Water Works Company IncASO Academy Sports and Outdoors IncGAB Gabelli Equity TrustSTRC Sarcos Technology and Robotics CorpRLMD Relmada Therapeutics IncLMND Lemonade IncNAACW North Atlantic Acquisition Equity Warrant Exp 20 Oct 2025 *W EXP 10/20/2025Go
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
HYHG.EU ProShares High Yield-Interest Rate Hedged
DIDIY DiDi Global Inc
AWK American Water Works Company Inc
ASO Academy Sports and Outdoors Inc
GAB Gabelli Equity Trust
STRC Sarcos Technology and Robotics Corp
RLMD Relmada Therapeutics Inc
LMND Lemonade Inc
NAACW North Atlantic Acquisition Equity Warrant Exp 20 Oct 2025 *W EXP 10/20/2025
Health Care : Biotechnology | Large Cap Value
Company profileModerna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.
Premarket |
|
|
| ||
Market Hours |
|
|
|
|
|
| Latest Earnings Beat Consensus (Q2 ending 06/2022) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced August 3, 2022 | $5.24 | Q2 Consensus of 13 analysts | $4.55 | Difference from consensus | 15.22% | Q3 Earnings will announce | (Unconfirmed) November 2, 2022 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
MRNA's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.